# IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

> **NCT07484113** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Stanford University** · enrollment: 10 (estimated)

## Conditions studied

- cGVHD

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** Sarilumab

## Key facts

- **NCT ID:** NCT07484113
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484113, "IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07484113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*